This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Zanubrutinib for Waldenstrom’s Macroglobulinemia

< Back

Zanubrutinib for Waldenstrom’s Macroglobulinemia


Cancer and Palliative Care

January 2018

Waldenstrom’s Macroglobulinaemia (WM) is a rare type of slow developing cancer which affects a type of cell of the immune system called B-cells. It is caused when abnormal B-cells build up in the bone marrow and other parts of the immune system which can block other normal blood cells from being produced. The abnormal B-cells also release large amounts of a protein called IgM which can build up in the blood making it thicker. People can live with WM for many years and will only usually receive treatment when the disease of symptoms begin to worsen. Treatments which are currently available include chemotherapy, stem cell transplants and plasma replacement.
Zanubrutinib is an oral drug taken twice a day which is currently in clinical trials for the treatment of patients with WM. Zanubrutinib works by blocking a protein called Bruton’s Tyrosine Kinase (BTK) in the abnormal B-cells which prevents the growth of these cells. As this drug specifically targets the abnormal B-cells, unlike chemotherapy drugs, this type of drug may provide fewer side effects than existing treatment for WM.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts